Abstract/References

There are increasing reports of patients with refractory otitis media caused by anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), especially myeloperoxidase (MPO)-ANCA-positive middle ear disease. However, making a definitive diagnosis can be difficult, which can adversely affect the outcome of treatment. We reviewed the diagnostic features of MPO-ANCA-positive middle ear disease and here discuss the difficulties of timely diagnosis and treatment. Seven cases were eligible (6 women, 1 man;aged 57-83 years), and all were MPO-ANCA positive and proteinase 3 (PR3)-ANCA negative. The patients were referred to our institution for management of intractable otitis media (2/7), progressive hearing loss (7/7) with facial palsy (1/7), and/or a high MPO-ANCA titer (5/7). All patients underwent tapering steroid therapy and their MPO-ANCA titer was monitored. Refractory MPO-ANCA-positive otitis media was noted:5 of 7 cases showed improvement with tapering steroid therapy but cure was not achieved in the remaining 2 cases. This study demonstrates the difficulties in the diagnosis and treatment of localized AAV. Early diagnosis and treatment can improve the prognosis of patients with AAV but global diagnostic criteria for ear disease have not been established. Additional cases should be prospectively examined to establish a treatment for MPO-ANCA-positive middle ear disease.

1. Kallenberg CG, Heeringa P, Stegeman CA, et al. Mechanism of Disease:pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol, 2:661-670, 2006.

2. Harigai M, Narita I, Sudo T, et al. anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) Practice Guideline 2023 (In Japanese). shindan to chiryosya, ISBN 978478782573, 2023.

3. Jennette JC. Overview of the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Clin Exp Nephrol, 17(5):603-606, 2013.

4. Nakamaru Y, Takagi D, Oridate N, et al. Otolaryngologic Manifestations of Antineutrophil Cytoplasmic Antibody Associated Vasculitis. Otolaryngology Head and Neck Surgery, 146:119-121, 2012.

5. Balow JE. Renal vasculitis. Curr Opin Nephrol Hypertens, 2:231-7, 1993.

6. Kallenberg CG. Pathogenesis of ANCA-associated vasculitides. Ann Rheum Dis, 70:i59-63, 2011.

7. Kallenberg CG. Anti-neutrophil cytoplasmic antibodies:current diagnostic and pathophysiological potential. Kidney Int, 46:1-15, 1994.

8. Savige J, Gillis D, Benson E, et al. International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol, 111:507-513, 1999.

9. Rao JK, Weinberger M, Oddone EZ, et al. The role of antineutrophil cytoplasmic antibody testing in the diagnosis of Wegener granulomatosis. Ann Intern Med, 123:925-932, 1995.

10. Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR project for ANCA assay standardization. Kidney Int, 53:743-753, 1998.

11. Kobayashi S, Fujimoto S. Epidemiology of vasculitides:differences between Japan, Europe and North America. Clin Exp Nephrol, 17:611-614, 2013.

12. Numano F. Differences in clinical presentation and outcome in different countries for Takayasu’s arteritis. Curr Opin Rheumatol, 9:12-15, 1997.

13. Watanabe K, Tani Y, Kimura H, et al. Clinical Outcomes of Japanese MPO-ANCA-related Nephritis: Significance of initial renal death for survival. Intern Med, 1969-1976, 2012.

14. Fujimoto S, Watts RA, Kobayashi S, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology (Oxford), 50:1916-1920, 2011.

15. Hashimoto H. Study on clinical epidemiology investigation between Japan and Europe of the ANCA-related vasculitis and diagnostic agent and therapy development 2007 (in Japanese).

16. Takagi D, Nakamaru Y, Maguchi S, et al. Otologic manifestations of Wegener’s granulomatosis. Laryngoscope, 112:1684-1690, 2002.

17. Fauci AS, Haynes BF, Katz P, et al. Wegener’s granulomatosis:prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med, 98:76-85, 1983.

18. Nicklasson B, Stangeland N. Wegener’s granulomatosis presenting as otitis media:J Laryngol Otol, 96:277-280, 1982.

19. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis:an analysis of 158 patients. Ann Intern Med, 116:488-498, 1992.

20. Devaney KO, Travis WD, Hoffman GS, et al. Interpretation of head and neck biopsies in Wegener’s granulomatosis. A pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol, 14: 555-564, 1990.

21. Travis WD, Hoffman GS, Leavitt RY, et al. Surgical pathology of the lung in Wegener’s granulo­matosis. Review of 87 open lung biopsies from 67 patients. Am J Surg Pathol, 15:315-333, 1991.

22. Yoshida N, Hara M, Hasegawa M, et al. Reversible Cochlear Function With ANCA-Associated Vasculitis Initially Diagnosed by Otologic Symptoms. Otology & Neurotology, 35:114-120, 2013.

23. McDonald TJ, DeRemee RA. Wegener’s granulomatosis. Laryngoscope, 93:220-231, 1983.

24. McDonald TJ, DeRemee RA, Weiland LH, et al. Wegener’s granulomatosis and polymorphic reticulosis-two disease or one? Arch Otolaryngol, 107:141-144, 1981.

25. Okamura H, Ohtani I, Anzai T, et al. The hearing loss in Wegener’s granulomatosis:relationship between hearing loss and serum ANCA. Auris Nasus Larynx, 19:1-6, 1992.

26. Ohtani I, Baba Y, Suzuki C, et al. Temporal bone pathology in Wegener’s granulomatosis. Fukushima J Med Sci, 46:31-39, 2000.

27. Harabuchi Y, Kishibe K, Tateyama K, et al. Clinical features and treatment outcomes of otitis media with antineutronphil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV):a retrospective analysis of 235 patients from a nationwide survey in Japan. Mod Rheumatol, 27(1):87-94, 2017.

28. Harabuchi Y, Kishibe K, Tateyama K, et al. Clinical characteristics, the diagnostic criteria and management recommendation of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV) proposed by Japan Otological Society. Auris Nasus Larynx, 48:2-14, 2021.

29. Yashiro-Furuya, et al. Outcome of rituximab treatment in Japanese patients with ANCA-associated vasculitis in daily clinical practice:A two-centre study in Fukushima, Japan. Mod Rheumatol, 33(2):352-359, 2023.

30. Kusumoto S, Tanaka Y, Mizokami M, et al. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol, 90:13-23, 2009.